Molecular and Immunological assessment of anticancer activity of 1,2,4-triazolo[4,3-b] [1,2,4] triazole derivative in combination with Artemisia Judaica Extract in Murine Lung cancer model.

Lung cancer remains a leading cause of cancer-related mortality worldwide, emphasizing the urgent need for innovative therapeutic strategies. This study evaluates the anti-cancer impact of Artemisia Judaica (AJ) and 1,2,4-triazole derivatives (TRI), both individually and in combination, against lung cancer. Immunohistochemical (IHC) analysis revealed significant modulation in the expression of Caspase-3, Caspase-7, and tumor necrosis factor-alpha (TNF-α), indicating enhanced apoptosis and immune responses. Molecular investigations further demonstrated the compounds’ regulatory effects on key oncogenic pathways, specifically EGFR and BRAF. Notably, the combined therapy displayed a synergistic effect, underscoring its potential as a novel therapeutic approach for lung cancer. These findings highlight AJ and 1,2,4-triazole derivatives as promising candidates for further clinical evaluation and development in lung cancer management.